Lmito Therapeutics Inc.
June 17, 2025
Company Presentation
Immunology
153C
Lmito, a JLABS Korea portfolio company, is an innovation-driven biotechnology company dedicated to developing novel and effective therapies for autoimmune/ neuroinflammatory diseases and fibrosis through the emerging concept of 'metabolic reprogramming' within diverse microenvironments.
Company HQ City:
Yongin-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2017
Lead Product in Development:
LMT503
CEO
Wheeseong Lee
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
Phase 1 IND approval of LMT801
What is your next catalyst (value inflection) update?
End of 2026
Website
lmito.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}